52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
May 17 (Reuters) - GT Biopharma Inc <GTBP.O>::GT BIOPHARMA REPORTS FIRST QUARTER 2021 RESULTS.Q1 LOSS PER SHARE $1.83.AS OF MARCH 31, 2021, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $27.6 MILLION, COMPARED TO $5.3 MILLION AS OF DECEMBER 31, 2020.
Feb 8 (Reuters) - GT Biopharma Inc <GTBP.PK>::GT BIOPHARMA - HAVE APPLIED TO LIST OUR COMMON STOCK ON NASDAQ CAPITAL MARKET UNDER SYMBOL “GTBP.” - SEC FILING.
Dec 11 (Reuters) - GT Biopharma Inc <GTBP.PK>::GT BIOPHARMA INC - INTEND TO APPLY TO LIST COMMON STOCK ON THE NASDAQ CAPITAL MARKET UNDER THE SYMBOL “GTBP.”.
Sept 24 (Reuters) - GT Biopharma Inc <GTBP.PK>::PRESS RELEASE - GT BIOPHARMA ANNOUNCES THE SALE OF ITS FIXED DOSE COMBINATION TABLET (GTB-004) FOR MYASTHENIA GRAVIS (CHRONIC AUTOIMMUNE DISEASE) TO DAS THERAPEUTICS.GT BIOPHARMA - TO RECEIVE $200,000 UP-FRONT PAYMENT, ANNUAL ROYALTIES OF 1.5% OF NET YEARLY SALES, $6 MILLION PAYMENT BASED ON COMMERCIAL MILESTONE.
May 30 (Reuters) - GT Biopharma Inc <GTBP.PK>::GT BIOPHARMA GTB-1550 CLINICAL DEVELOPMENT UPDATE.GT BIOPHARMA INC - DURABLE COMPLETE REMISSION IN PATIENT CURRENTLY DISEASE-FREE AT 50 MONTHS POST TREATMENT.GT BIOPHARMA INC - GREATER THAN 50% OF EVALUABLE PATIENTS RECEIVING 60 MG/KG DOSE HAD POSITIVE CLINICAL RESPONSE.GT BIOPHARMA INC - PLANNING TO PROCEED WITH A PHASE II CLINICAL TRIAL FOR GTB-1550.
April 8 (Reuters) - GT Biopharma Inc <GTBP.PK>::GT BIOPHARMA RECEIVES INSTITUTIONAL REVIEW BOARD APPROVAL TO PROCEED WITH IN HUMAN FDA PHASE 1 CLINICAL TRIAL.
March 26 (Reuters) - GT Biopharma Inc <GTBP.PK>::GT BIOPHARMA ANNOUNCES COMPLETION OF MANAGEMENT RESTRUCTURING.GT BIOPHARMA INC - ANTHONY J CATALDO HAS BEEN NAMED CHAIRMAN AND CHIEF EXECUTIVE OFFICER.GT BIOPHARMA INC - STEVEN WELDON HAS BEEN APPOINTED AS CHIEF FINANCIAL OFFICER AND A MEMBER OF BOARD.
Dec 18 (Reuters) - GT Biopharma Inc <GTBP.PK>::GT BIOPHARMA INC - FILED AN APPLICATION TO LIST ITS COMMON STOCK ON NASDAQ CAPITAL MARKET.
Oxis International Inc:Says Oxis Biotech Inc, subsidiary announced today the execution of the amendment to its current exclusive option agreement with the University of Pittsburgh related.To certain patent rights developed by Dr. Xiang-Qun Xie, Associate Dean for Research Innovation and Professor, Pharmaceutical Sciences, School of Pharmacy.Patent rights relate to addition of certain novel compositions-of-matter which could prove useful as therapeutics for treatment of various human diseases.
OXIS International, Inc:Says the resignation of Ken Eaton, the election of Anthony J. Cataldo as Chief Executive Officer, and Steven Weldon as President.Effective Nov. 19, 2014, Ken Eaton resigned his positions as Chief Executive Officer and member of the Board of Directors of Oxis International, Inc. to pursue new opportunities.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.